Infliximab or biosimilars in sarcoidosis; to switch or not to switch?

Infliximab or biosimilars in sarcoidosis; to switch or not to switch?

Authors

  • M. Veltkamp ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands
  • M. Drent ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands; Dept of Pharmacoloogy and Toxicology, FHML, University Maastricht, The Netherlands
  • R. P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic, Dept of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, USA

Abstract

Not available

Downloads

Published

15-01-2016

Issue

Vol. 32 No. 4 (2015)

Section

Editorial

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

1.
Veltkamp M, Drent M, Baughman RP. Infliximab or biosimilars in sarcoidosis; to switch or not to switch?. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2016 Jan. 15 [cited 2025 Jun. 22];32(4):280-3. Available from: https://mattioli1885journals.com/index.php/sarcoidosis/article/view/5001